Understand the source comparison
Peptides vs SARMs — Which Works Best for Research?
Research from the University of Michigan found that over 60% of athletic performance studies conflate peptides with SARMs despite fundamentally different mechanisms of action—one triggers your body's own hormone production pathways, the other mimics testostero
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research from the University of Michigan found that over 60% of athletic performance studies conflate peptides with SARMs despite fundamentally different mechanisms of action—one triggers your body's own hormone production pathways, the other mimics testosterone by binding androgen receptors directly. The distinction matters because regulatory bodies, research protocols, and safety profiles diverge sharply between these two compound classes.
- We've synthesized hundreds of research-grade peptides across categories from growth hormone secretagogues to metabolic modulators. The confusion between peptides vs SARMs creates compliance risks and experimental design failures that most protocol documents never address.
- What is the difference between peptides and SARMs?
- Peptides are short chains of amino acids (typically 2–50 residues) that signal endogenous pathways through receptor binding—triggering your body's own hormone production. SARMs (Selective Androgen Receptor Modulators) are synthetic compounds that directly occupy androgen receptors to mimic testosterone's tissue-selective anabolic effects without converting to DHT or estrogen. Peptides work through amplification of natural processes; SARMs work through receptor substitution.
- This isn't just semantic. Peptides like CJC1295 Ipamorelin stimulate pituitary gland release of growth hormone—your body decides how much to produce based on negative feedback loops. SARMs like ostarine bind androgen receptors in muscle tissue directly, bypassing hypothalamic-pituitary-gonadal axis regulation entirely. One respects homeostasis; the other overrides it. This article covers mechanism differences, legal classification under FDA and DEA schedules, half-life and dosing implications, tissue selectivity profiles, and why peptide suppliers like Real Peptides focus exclusively on the former category.